AC Immune SA announced several executive appointments effective January 1, 2025, as part of its succession planning and to optimize Research and Development operations. Mark Danton will be promoted to Executive Vice President AI/IS, reflecting the increasing importance of Artificial Intelligence, Digital Technologies, and Information Systems.
Dr. Günther Staffler will assume the role of Senior Vice President of Immunotherapy, and Dr. Francesca Capotosti will become Vice President of Research. Dr. Staffler joined AC Immune in 2021 following the acquisition of assets including the alpha-synuclein active immunotherapy candidate, ACI-7104.056.
Concurrently, Dr. Madiha Derouazi, the current Chief Scientific Officer, will depart the company at the end of December 2024 by mutual consent. These changes aim to strategically align the company's leadership with its evolving research and development priorities.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.